Results 191 to 200 of about 92,350 (272)

Monoclonal Antibody Dispensing Around Pregnancy: A Descriptive Analysis Using Electronic Health Records in Italy

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Purpose To describe trends in dispensing of monoclonal antibody biologics (mAbs) for autoimmune conditions during and around pregnancy. Methods We conducted a population‐wide study of women of reproductive age (14–49 years) resident in Lombardy, Italy, between 2012 and 2024.
Elisabeth Aiton   +8 more
wiley   +1 more source

Sustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndrome

open access: yes
HemaSphere, Volume 10, Issue 11, November 2026.
Bhavisha A. Patel   +34 more
wiley   +1 more source

Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 11, November 2026.
ABSTRACT Introduction Non‐infectious uveitis (NIU) is a chronic immune‐mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conventional agents and biologics, remain incompletely defined.
Kai‐Yang Chen   +2 more
wiley   +1 more source

Efficacy and safety of interleukin-6 receptor inhibitors in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review and meta-analysis. [PDF]

open access: yesTher Adv Neurol Disord
Ali A   +13 more
europepmc   +1 more source

Infections and their determinants in patients with non‐Hodgkin lymphoma receiving bispecific T‐cell antibodies: Results from an international multicenter cohort study

open access: yes
HemaSphere, Volume 10, Issue 11, November 2026.
Zainab Shahid   +17 more
wiley   +1 more source

A PK‐Driven Quantitative Systems Pharmacology Model Predicts Cytokine Release Syndrome Severity Across T Cell‐Activating Therapies via a Locked Cytokine Amplification Network

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Cytokine release syndrome (CRS) is a major dose‐limiting toxicity of T cell‐engaging immunotherapies. Existing CRS models are drug‐class‐specific; here we show that a single locked cytokine network captures CRS severity across mechanistically distinct drug classes, changing only drug‐specific upstream activation parameters.
Hajar Besbassi
wiley   +1 more source

Reactivation of Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Undergoing Tocilizumab Treatment. [PDF]

open access: yesAm J Trop Med Hyg
de Souza RM   +6 more
europepmc   +1 more source

Bayesian Methods Incorporating Baseline Covariates for Borrowing Historical Control Data in Randomized Clinical Trials: A Neutral Comparison Study

open access: yesStatistics in Medicine, Volume 45, Issue 25-27, November 2026.
ABSTRACT The idea of leveraging historical control data in randomized clinical trials (RCTs) has gained a lot of attention, in particular for rare disease and pediatric indications where conducting traditional and fully powered RCTs can be challenging.
David Jesse   +4 more
wiley   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2180-2190, November 2026.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy